WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo takes on Hard-to-Treat waldenstrom macroglobulinemia
Disease control Not yet recruitingThis phase II trial is testing the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with relapsed or refractory Waldenstrom Macroglobulinemia, a rare blood cancer. Participants must have had at least one prior treatment. The study aim…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New triple-drug attack targets rare blood cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 19 adults who have not yet been t…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy targets blood cancer relapse
Disease control Not yet recruitingThis study tests a combination of two oral drugs, zanubrutinib and BGB-11417, in adults with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combination can shrink or control the cancer better than current options. P…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC